Improvement was further evidenced by a decrease in pruritus score and the surface area of lesions.

Additionally, exploratory investigation was performed on the efficacy for disease severity and pruritus score in AD patients.

Statistically significant differences as compared to placebo were not achieved for the erythema or pruritus scores, which were less severe at baseline, the company said.